Cardiff Oncology (NASDAQ:CRDF – Get Free Report) will be posting its quarterly earnings results after the market closes on Thursday, May 2nd. Analysts expect Cardiff Oncology to post earnings of ($0.25) per share for the quarter. Individual interested in participating in the company’s earnings conference call can do so using this link. Cardiff Oncology (NASDAQ:CRDF […]
Cardiff Oncology, Inc. (NASDAQ:CRDF – Get Free Report) Director Gary W. Pace acquired 30,000 shares of the company’s stock in a transaction that occurred on Tuesday, December 19th. The shares were bought at an average cost of $1.37 per share, for a total transaction of $41,100.00. Following the transaction, the director now owns 697,761 shares […]
Cardiff Oncology, Inc. (NASDAQ:CRDF – Get Free Report) was the recipient of a significant decrease in short interest in November. As of November 30th, there was short interest totalling 1,450,000 shares, a decrease of 9.4% from the November 15th total of 1,600,000 shares. Based on an average daily trading volume, of 688,500 shares, the short-interest […]
Cardiff Oncology, Inc. (NASDAQ:CRDF – Get Free Report) was the target of a large drop in short interest in October. As of October 15th, there was short interest totalling 1,530,000 shares, a drop of 24.6% from the September 30th total of 2,030,000 shares. Based on an average daily volume of 1,100,000 shares, the short-interest ratio […]
Cardiff Oncology, Inc. (NASDAQ:CRDF – Get Free Report) was the recipient of a large growth in short interest during the month of September. As of September 15th, there was short interest totalling 673,000 shares, a growth of 25.4% from the August 31st total of 536,500 shares. Based on an average daily trading volume, of 609,800 […]